AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32712307 — intervention group
Group type: COMPARATOR
Intervention: Tonic water (control)
Number of subjects: 194
Study 36483117 — intervention group
Group type: EXPERIMENTAL
Intervention: WW + PolyRules!
Number of subjects: 30
Study 36483117 — intervention group
Group type: COMPARATOR
Intervention: WW
Number of subjects: 30
Study 32253540 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal school-based mental health program combining mental health literacy and dialectical behavior skills
Number of subjects: 113
Study 32253540 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 113
Study 34520520 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (5 mcg/kg)
Number of subjects: 79
Study 34520520 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal saline (placebo)
Number of subjects: 79
Study 34666202 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt (220 g/d)
Number of subjects: 92
Study 34666202 — intervention group
Group type: COMPARATOR
Intervention: Milk (220 g/d)
Number of subjects: 92
Study 33711262 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 prevalence (combined measure)
Number of subjects: 4258
Study 33711262 — intervention group
Group type: EXPERIMENTAL
Intervention: rtPCR-positive prevalence
Number of subjects: 4258
Study 33711262 — intervention group
Group type: EXPERIMENTAL
Intervention: ELISA-positive prevalence
Number of subjects: 4258
Study 33711262 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated number of SARS-CoV-2 infections
Number of subjects: 4258
Study 32129141 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of GO-ON (5 mL)
Number of subjects: 127
Study 32129141 — intervention group
Group type: COMPARATOR
Intervention: Three repeated doses of GO-ON (2.5 mL each)
Number of subjects: 127
Study 32129141 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of single-dose injection
Number of subjects: 127
Study 36244014 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde intrarenal surgery (RIRS)
Number of subjects: 90
Study 36244014 — intervention group
Group type: COMPARATOR
Intervention: mini-percutaneous nephrolithotomy (mini-PCNL)
Number of subjects: 90
Study 36244014 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RIRS and mini-PCNL
Number of subjects: 90
Study 33832352 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 4744
Study 33832352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4744
Study 36085065 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided meditation for 6 weeks
Number of subjects: 80
Study 36085065 — intervention group
Group type: COMPARATOR
Intervention: Control group (no guided meditation)
Number of subjects: 80
Study 36255339 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritual Care (SC) for 3 days
Number of subjects: 145
Study 36255339 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 145
Study 34636210 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal-triangular flap
Number of subjects: 60
Study 34636210 — intervention group
Group type: COMPARATOR
Intervention: Szmyd flap
Number of subjects: 60
Study 34636210 — intervention group
Group type: COMPARATOR
Intervention: Envelope flap
Number of subjects: 60
Study 35511258 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (N = 27)
Number of subjects: 53
Study 35511258 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N = 26)
Number of subjects: 53
Study 33762075 — intervention group
Group type: EXPERIMENTAL
Intervention: 6Pa200MZ
Number of subjects: 203
Study 33762075 — intervention group
Group type: EXPERIMENTAL
Intervention: 4Pa200MZ
Number of subjects: 203
Study 33762075 — intervention group
Group type: EXPERIMENTAL
Intervention: 4Pa100MZ
Number of subjects: 203
Study 33762075 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 203
Study 33762075 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental regimens
Number of subjects: 203
Study 35394987 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging intervention
Number of subjects: 824
Study 33201535 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1, 0.2, or 0.3 mg/kg bumetanide
Number of subjects: 43
Study 33201535 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 43
Study 35694704 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI examination (group B)
Number of subjects: 96
Study 35694704 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopy (group A)
Number of subjects: 96
Study 35694704 — intervention group
Group type: EXPERIMENTAL
Intervention: SMASH algorithm
Number of subjects: 96
Study 35694704 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional SOS algorithm
Number of subjects: 96
Study 34346136 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial scratching
Number of subjects: 0
Study 34346136 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 35272940 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin injection during ovarian cystectomy
Number of subjects: 120
Study 35272940 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vasopressin injection)
Number of subjects: 120
Study 35272940 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (vasopressin and control)
Number of subjects: 120
Study 32310706 — intervention group
Group type: EXPERIMENTAL
Intervention: Best-Corrected Visual Acuity (BCVA)
Number of subjects: 2018
Study 32310706 — intervention group
Group type: EXPERIMENTAL
Intervention: Presenting Visual Acuity (PVA)
Number of subjects: 2018
Study 32310706 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and Central Corneal Thickness
Number of subjects: 2018
Study 32310706 — intervention group
Group type: EXPERIMENTAL
Intervention: Causes of impaired BCVA
Number of subjects: 2018
Study 36227421 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine group (group N, 0.375% ropivacaine 40 ml + normal saline 4 ml)
Number of subjects: 90
Study 36227421 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate group (group M, 0.375% ropivacaine 40 ml + 10% magnesium sulfate 4 ml)
Number of subjects: 90
Study 36227421 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C, normal saline 44 ml)
Number of subjects: 90
Study 33472301 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation
Number of subjects: 129
Study 33472301 — intervention group
Group type: EXPERIMENTAL
Intervention: Betahistine (12 mg orally three times a day for four weeks)
Number of subjects: 129
Study 33472301 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific treatment)
Number of subjects: 129
Study 32499125 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (18 sessions over 6 weeks)
Number of subjects: 519
Study 32499125 — intervention group
Group type: COMPARATOR
Intervention: PEG 4000 (20 g/d for IBS-C) / Pinaverium bromide (150 mg/d for IBS-D)
Number of subjects: 519
Study 32499125 — intervention group
Group type: EXPERIMENTAL
Intervention: Between-group comparison
Number of subjects: 519
Study 35241246 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily
Number of subjects: 6263
Study 35241246 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 6263
Study 36333810 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent training (Multi)
Number of subjects: 80
Study 36333810 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent training + self-management strategies (Multi+SM)
Number of subjects: 80
Study 34116873 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-antigen hepatitis B vaccine (3A-HBV) lot A
Number of subjects: 267
Study 34116873 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-antigen hepatitis B vaccine (3A-HBV) lot B
Number of subjects: 267
Study 34116873 — intervention group
Group type: COMPARATOR
Intervention: 1-antigen hepatitis B vaccine (1A-HBV) Engerix-B
Number of subjects: 267
Study 36028413 — intervention group
Group type: EXPERIMENTAL
Intervention: Family‐Centered Empowerment Model (FCEM)
Number of subjects: 50
Study 36028413 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 50
Study 32193758 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep belief network model using Macc 166 bit features
Number of subjects: 0
Study 32193758 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep belief network model using PubChem 881 bit features
Number of subjects: 0
Study 32193758 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep belief network model using Morgan 2048 bit features
Number of subjects: 0
Study 32193758 — intervention group
Group type: EXPERIMENTAL
Intervention: Model performance with external data from drug banks and ZINC database
Number of subjects: 0
Study 32193758 — intervention group
Group type: EXPERIMENTAL
Intervention: Misclassified non-drug small molecules
Number of subjects: 0
Study 32803003 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of country-specific public recommendations regarding vaccinations
Number of subjects: 3652
Study 32803003 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge about vaccinations against measles, influenza, and HPV
Number of subjects: 3652
Study 32803003 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitudes concerning vaccinations in general and for healthcare workers (HCWs)
Number of subjects: 3652
Study 34648948 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 0
Study 33482247 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib, 400 mg daily for 2 years
Number of subjects: 908
Study 33482247 — intervention group
Group type: COMPARATOR
Intervention: No further therapy after surgery
Number of subjects: 908
Study 33727409 — intervention group
Group type: EXPERIMENTAL
Intervention: Early antihypertensive treatment, aimed at average systolic BP reduction by 10%-20% within the first 24 hours and achieving BP <140/90 mm Hg within 5 days.
Number of subjects: 0
Study 33727409 — intervention group
Group type: COMPARATOR
Intervention: Delayed antihypertensive treatment, no antihypertensive medications for the first 7 days, then achieving BP <140/90 mm Hg after 7 days.
Number of subjects: 0
Study 32851636 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6.5 mg·kg‐1 body mass)
Number of subjects: 29
Study 32851636 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate (6 g of maltodextrin rinsed for 10 s)
Number of subjects: 29
Study 32851636 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine plus carbohydrate
Number of subjects: 29
Study 32851636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 36173609 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (50 mg once daily for 12 weeks)
Number of subjects: 100
Study 36173609 — intervention group
Group type: COMPARATOR
Intervention: Placebo (once daily for 12 weeks)
Number of subjects: 100
Study 33550634 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense pulsed light (IPL)
Number of subjects: 22
Study 33550634 — intervention group
Group type: COMPARATOR
Intervention: Q-switched neodymium-doped yttrium aluminum garnet laser (QS)
Number of subjects: 22
Study 36158665 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous paclitaxel 135 mg/m2 plus mFOLFOX6
Number of subjects: 90
Study 36158665 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal paclitaxel 80 mg/m2 plus mFOLFOX6
Number of subjects: 90
Study 36158665 — intervention group
Group type: COMPARATOR
Intervention: mFOLFOX6
Number of subjects: 90
Study 33814441 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Bifidobacterium breve MCC1274
Number of subjects: 0
Study 35037057 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 220
Study 35037057 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean/low-carbohydrate diet
Number of subjects: 220
Study 35037057 — intervention group
Group type: EXPERIMENTAL
Intervention: Added physical activity
Number of subjects: 220
Study 35037057 — intervention group
Group type: EXPERIMENTAL
Intervention: No added physical activity
Number of subjects: 220
Study 35037057 — intervention group
Group type: COMPARATOR
Intervention: Overall association
Number of subjects: 220
Study 35037057 — intervention group
Group type: COMPARATOR
Intervention: Interaction with baseline fasting plasma glucose
Number of subjects: 220
Study 33077155 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative axillary ultrasound (AUS)
Number of subjects: 462
Study 34717672 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving condition (congruent moving virtual hand)
Number of subjects: 20
Study 34717672 — intervention group
Group type: COMPARATOR
Intervention: Static condition (static virtual hand)
Number of subjects: 20
Study 34717672 — intervention group
Group type: COMPARATOR
Intervention: Hidden condition (no virtual hand)
Number of subjects: 20
Study 35280907 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab (single 400 mg dose in two 200 mg subcutaneous injections)
Number of subjects: 30
Study 35280907 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 30
Study 35280907 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab
Number of subjects: 30
Study 35280907 — intervention group
Group type: COMPARATOR
Intervention: Sarilumab and Standard care
Number of subjects: 30
Study 33164259 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine or spironolactone (fourth drug)
Number of subjects: 103
Study 33164259 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum asymmetric dimethylarginine (ADMA)
Number of subjects: 103
Study 33164259 — intervention group
Group type: COMPARATOR
Intervention: Treatment with antihypertensive drugs (first phase V0-V3)
Number of subjects: 103
Study 36400418 — intervention group
Group type: EXPERIMENTAL
Intervention: ANT14 (14 days of antofloxacin-based bismuth quadruple therapy)
Number of subjects: 1174
Study 36400418 — intervention group
Group type: EXPERIMENTAL
Intervention: ANT10 (10 days of antofloxacin-based bismuth quadruple therapy)
Number of subjects: 1174
Study 36400418 — intervention group
Group type: COMPARATOR
Intervention: CLA14 (14 days of clarithromycin-based bismuth quadruple therapy)
Number of subjects: 1174
Study 36400418 — intervention group
Group type: EXPERIMENTAL
Intervention: ANT10 and ANT14
Number of subjects: 1174
Study 33954933 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral abrocitinib 200 mg
Number of subjects: 942
Study 33954933 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral abrocitinib 100 mg
Number of subjects: 942
Study 33954933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 942
Study 33594987 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexcom G5 Mobile (DG5)
Number of subjects: 11
Study 33594987 — intervention group
Group type: COMPARATOR
Intervention: Eversense (EVS)
Number of subjects: 11
Study 35397122 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy
Number of subjects: 62
Study 35397122 — intervention group
Group type: COMPARATOR
Intervention: No preoperative chemotherapy
Number of subjects: 62
Study 32365675 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dosed milk protein hydrolysate
Number of subjects: 0
Study 32365675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34198250 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided EVT technique
Number of subjects: 479
Study 33053626 — intervention group
Group type: EXPERIMENTAL
Intervention: EOD‐1PM
Number of subjects: 66
Study 33053626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 36419389 — intervention group
Group type: EXPERIMENTAL
Intervention: CALM intervention
Number of subjects: 90
Study 36419389 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 90
Study 33599841 — intervention group
Group type: EXPERIMENTAL
Intervention: De-escalation treatment options (cetuximab-based radiotherapy)
Number of subjects: 0
Study 33599841 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (IC) protocols
Number of subjects: 0
Study 33599841 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxicity reporting
Number of subjects: 0
Study 33599841 — intervention group
Group type: COMPARATOR
Intervention: De-intensified strategies
Number of subjects: 0
Study 33241599 — intervention group
Group type: EXPERIMENTAL
Intervention: Thulium laser enucleation of the prostate
Number of subjects: 140
Study 33241599 — intervention group
Group type: COMPARATOR
Intervention: Bipolar transurethral resection of the prostate
Number of subjects: 140
Study 34052121 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful breath awareness & muscle relaxation (MBMR)
Number of subjects: 30
Study 34052121 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial electrical stimulation (tCES)
Number of subjects: 30
Study 34052121 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful breath awareness & muscle relaxation + Transcranial electrical stimulation (MBMR+tCES)
Number of subjects: 30
Study 33499531 — intervention group
Group type: EXPERIMENTAL
Intervention: iPad measurement of near point of convergence (NPC)
Number of subjects: 50
Study 33499531 — intervention group
Group type: EXPERIMENTAL
Intervention: iPad measurement of distance visual acuity
Number of subjects: 50
Study 33499531 — intervention group
Group type: EXPERIMENTAL
Intervention: Convergence Insufficiency Symptom Survey
Number of subjects: 50
Study 33499531 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading fluency assessment using iPad
Number of subjects: 50
Study 33499531 — intervention group
Group type: EXPERIMENTAL
Intervention: iPad measurement of NPC
Number of subjects: 50
Study 35485512 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (propofol induction + sevoflurane/remifentanil maintenance)
Number of subjects: 100
Study 35485512 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (propofol induction + desflurane/remifentanil maintenance)
Number of subjects: 100
Study 35485512 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (pentothal induction + desflurane/remifentanil maintenance)
Number of subjects: 100
Study 35485512 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 4 (pentothal induction + sevoflurane/remifentanil maintenance)
Number of subjects: 100
Study 33755110 — intervention group
Group type: EXPERIMENTAL
Intervention: PN-HPT (4.0 mL)
Number of subjects: 20
Study 33755110 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4.0 mL normal saline)
Number of subjects: 20
Study 35232423 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg oral Dydrogesterone daily
Number of subjects: 150
Study 35232423 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg intramuscular 17α‐OHPC weekly
Number of subjects: 150
Study 35232423 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 150
Study 33946203 — intervention group
Group type: EXPERIMENTAL
Intervention: KEPT-app (Kegel Exercise Pregnancy Training app)
Number of subjects: 64
Study 33946203 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 64
Study 35668036 — intervention group
Group type: EXPERIMENTAL
Intervention: Pare de Fumar Conosco
Number of subjects: 0
Study 35668036 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 35668036 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 0
Study 33818170 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafluprost (15 mg/ml)
Number of subjects: 64
Study 33818170 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost (0.1 mg/ml)
Number of subjects: 64
Study 33818170 — intervention group
Group type: COMPARATOR
Intervention: Comparison of tafluprost and bimatoprost
Number of subjects: 64
Study 32910712 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted education
Number of subjects: 140
Study 32910712 — intervention group
Group type: COMPARATOR
Intervention: Traditional face-to-face discussion
Number of subjects: 140
Study 35357881 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (β-blocker)
Number of subjects: 0
Study 35357881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33706001 — intervention group
Group type: EXPERIMENTAL
Intervention: Native CHOICES intervention (2 motivational interviewing sessions, elective contraception counseling session, electronic messaging)
Number of subjects: 0
Study 33706001 — intervention group
Group type: COMPARATOR
Intervention: Services-as-usual, waitlist control condition
Number of subjects: 0
Study 32122898 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dalbavancin at 1,500 mg
Number of subjects: 10
Study 32122898 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal dalbavancin at 1,500 mg
Number of subjects: 10
Study 616803936 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative education
Number of subjects: 130
Study 616803936 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preoperative education)
Number of subjects: 130
Study 35748757 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group (external concurrent occipital and trigeminal neurostimulation)
Number of subjects: 131
Study 35748757 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 131
Study 34468609 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical incision
Number of subjects: 61
Study 34468609 — intervention group
Group type: COMPARATOR
Intervention: Transversal incision
Number of subjects: 61
Study 33502291 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-assessed moderate or severe asthma
Number of subjects: 1828
Study 33502291 — intervention group
Group type: EXPERIMENTAL
Intervention: Age >60 years
Number of subjects: 1828
Study 33502291 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergic rhino-conjunctivitis
Number of subjects: 1828
Study 33502291 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinusitis
Number of subjects: 1828
Study 33502291 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor asthma control (ACT <20)
Number of subjects: 1828
Study 33502291 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency care visits the previous year
Number of subjects: 1828
Study 33502291 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower level of education (women)
Number of subjects: 1828
Study 33502291 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower level of education (men)
Number of subjects: 1828